Currently out of the existing stock ratings of Cory Kasimov, 48 are a HOLD (28.4%), 119 are a BUY (70.41%), 2 are a SELL (1.18%).

Cory Kasimov

Work Performance Price Targets & Ratings Chart

Analyst Cory Kasimov, currently employed at EVERCORE, carries an average stock price target met ratio of 66.18% that have a potential upside of 35.11% achieved within 339 days. Previously, Cory Kasimov worked at JPMORGAN.

Cory Kasimov’s has documented 318 price targets and ratings displayed on 40 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on BBIO, BridgeBio Pharma at 08-May-2026.

Wall Street Analyst Cory Kasimov

Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.

Average potential price target upside

of $64.29 (51.57%) on BL (BLACKLINE).
of $50.56 (18.9%) on BIIB (BIOGEN).
of $40.63 (26.04%) on VRTX (VERTEX PHARMACEUTICALS).

ACAD ACADIA Pharmaceuticals ALKS Alkermes Plc BLUE Bluebird bio BMRN Biomarin Pharmaceutical BNTX BioNTech SE CLVS Clovis Oncology GILD Gilead Sciences INCY yte MRNA Moderna NVCR Novocure Ltd PBYI Puma Biotechnology RARE Ultragenyx SANA Sana Biotechnology VRTX Vertex Pharmaceuticals SAGE Sage Therapeutic AMGN Amgen CERE Cerevel Therapeutics Holdings EDIT Editas Medicine GBT Global Blood Therapeutics KRTX Karuna Therapeutics REGN Regeneron Pharmaceuticals BIIB Biogen CELG Celgene JNCE Jounce Therapeutics LEGN Legend Biotech Corp BBIO BridgeBio Pharma EWTX Edgewise Therapeutics SWTX SpringWorks Therapeutics CYTK Cytokinetics GWPH GW Pharmaceuticals plc NBIX Neurocrine Biosciences SGEN Seagen SMMT Summit Therapeutics PLC IMNM Immunome ACLX Arcellx BL Blackline LIFE aTyr Pharma ONCE Spark Therapeutics VIR Vir Biotechnology XENE Xenon Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Brian Abrahams (RBC)